Results 71 to 80 of about 1,937,940 (311)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

PSMD14-mediated deubiquitination of CARM1 facilitates the proliferation and metastasis of hepatocellular carcinoma by inducing the transcriptional activation of FERMT1

Cell Death and Disease
Hepatocellular carcinoma (HCC) is a highly potent malignancy. The enzyme coactivator-associated arginine methyltransferase 1 (CARM1) is highly expressed in different types of cancer.
Jing Lu, Huita Wu, Ping Zhan, Yuyan Lu, Qinliang Fang, Changhong Luo, Fuqiang Wang, Jing Wen, Chengrong Xie, Zhenyu Yin   +9 more
doaj   +1 more source

Case Report: Long-term disease-free survival in an advanced hepatocellular carcinoma patient: an exceptional response to PD-1 inhibitor therapy

Frontiers in Immunology
IntroductionHepatocellular carcinoma (HCC) is a leading cause of cancer-related death, with most patients diagnosed at advanced stages, often precluding surgical resection.
Qinliang Fang, Qinliang Fang, Shuqi Yu, Yu Xiong, Yu Xiong, Yibin Zhang, Yibin Zhang, Xiaomin Wang, Xiaomin Wang, Jianyin Zhou, Jianyin Zhou, Fuqiang Wang, Fuqiang Wang, Zhenyu Yin, Zhenyu Yin   +14 more
doaj   +1 more source

Advances in the interventional therapy of hepatocellular carcinoma originating from the caudate lobe

Journal of Interventional Medicine, 2022
Hepatocellular carcinoma originating from the caudate lobe, also known as segment I hepatocellular carcinoma, is difficult to treat because of its special location, complex vascular supply, and the proximity of important vessels, bile ducts, and organs ...
Shanmiao Ke
doaj   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Enhanced expression of miR-889 forecasts an unfavorable prognosis and facilitates cell progression in hepatocellular carcinoma

Diagnostic Pathology, 2021
Background As a new type of molecular marker, microRNAs (miRNAs) can be used for early diagnosis and prognosis prediction of malignant tumors, and has broad clinical application prospects.
He Wang, Huiwen Wang, Wenyu Cui, Qiao Zhang, Jing Li, Qi Zhang   +5 more
doaj   +1 more source

Laparoscopy in liver transplantation: The future has arrived [PDF]

, 2012
In the last two decades, laparoscopy has revolutionized the field of surgery. Many procedures previously performed with an open access are now routinely carried out with the laparoscopic approach.
Berloco, Pasquale Bartolomeo, Di Laudo, Marco, Frattaroli, Fabrizio Maria, Guglielmo, Nicola, Lai, Quirino, LEVI SANDRI, GIOVANNI BATTISTA, Melandro, Fabio, Rafael S., Pinheiro, Rossi, Massimo, Spoletini, Gabriele   +9 more
core   +2 more sources

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. [PDF]

, 2020
BackgroundTransforming growth factor beta (TGF-β) signalling is involved in the development of hepatocellular carcinoma (HCC). We followed changes in biomarkers during treatment of patients with HCC with the TGF-βRI/ALK5 inhibitor galunisertib ...
Benhadji, Karim A, Cleverly, Ann, Estrem, Shawn T, Faivre, Sandrine, Gane, Ed, Giannelli, Gianluigi, Kelley, Robin K, Lahn, Michael M, Man, Michael, Paradis, Valerie, Raymond, Eric, Santoro, Armando, Smith, Claire, Wang, Shuaicheng   +13 more
core   +2 more sources

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Protein arginine N-methyltransferase 1 promotes the proliferation and metastasis of hepatocellular carcinoma cells

Tumor Biology, 2017
Hepatocellular carcinoma is the most common subtype of liver cancer. Protein arginine N-methyltransferase 1 was shown to be upregulated in various cancers.
Qing Gou, ShuJiao He, ZeJian Zhou
doaj   +1 more source